ACTG 265--SAFETY AND IMMUNOGENICITY OF LIVE ATTENUATED VARICELLA VACCINE

这项研究是一项I/II期的儿科ACTG安全性和 HIV感染者水痘减毒活疫苗的免疫原性研究 免疫缺陷程度最低的儿童。其目的是研究 水痘减毒活疫苗对感染艾滋病毒儿童的效果。 需要回答的主要问题涉及疫苗的安全性， 在这些患者中使用时，以及这些药物在多大程度上 受试者能够对疫苗产生免疫反应。数据 来自有野生病史的HIV感染者的对照组 型水痘，将被收集。这些数据将被用于检查 疫苗是否能够激发类似于 这些人加强了对疾病本身的抗击。

This study is a phase I/II pediatric ACTG trial of the safety and immunogenicity of live attenuated varicella vaccine in HIV-infected children with minimal immunodeficiency. The purpose is to examine the effects of a live-attenuated varicella vaccine on HIV-infected children. The primary questions to be answered concern the safety of the vaccine, when used within this patient population, and the extent to which these subjects are capable of mounting an immune response to the vaccine. Data from a comparison group of HIV-infected subjects with a history of wild type varicella, will be collected. The data will be used to examine whether the vaccine is capable of evoking immune responses similar to those mounted against the disease itself.